Evidence map›Paper›PMID 34845448›Full record

ArticlebioRxiv : the preprint server for biology2021

Stabilization of the SARS-CoV-2 Receptor Binding Domain by Protein Core Redesign and Deep Mutational Scanning.

Alison C Leonard, Jonathan J Weinstein, Paul J Steiner, Annette H Erbse, Sarel J Fleishman, Timothy A Whitehead

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Alison C LeonardDepartment of Chemical and Biological Engineering, University of Colorado, Boulder, CO 80305, USA.ORCID 0000-0002-1642-9632
Jonathan J WeinsteinDepartment of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel.
Paul J SteinerDepartment of Chemical and Biological Engineering, University of Colorado, Boulder, CO 80305, USA.
Annette H ErbseDepartment of Biochemistry, University of Colorado, Boulder, CO.
Sarel J FleishmanDepartment of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel.
Timothy A WhiteheadDepartment of Chemical and Biological Engineering, University of Colorado, Boulder, CO 80305, USA.ORCID 0000-0003-3177-1361
University of Colorado Boulder · USWeizmann Institute of Science · IL

Funding

Predoctoral Training Molecular BiophysicsT32GM065103 · NIGMS · UNIVERSITY OF COLORADO AT BOULDER · PI FALKE, JOSEPH J · 2002 to 2021
$4.3M
The influence of evolutionary landscapes on protective antibody developmentR01AI141452 · NIAID · UNIVERSITY OF COLORADO · PI WHITEHEAD, TIMOTHY ANDREW · 2019 to 2023
$2.8M
NIAID NIH HHS R01 AI141452NIGMS NIH HHS T32 GM065103
6 · The paper itself

Abstract

Stabilizing antigenic proteins as vaccine immunogens or diagnostic reagents is a stringent case of protein engineering and design as the exterior surface must maintain recognition by receptor(s) and antigen-specific antibodies at multiple distinct epitopes. This is a challenge, as stability-enhancing mutations must be focused on the protein core, whereas successful computational stabilization algorithms typically select mutations at solvent-facing positions. In this study we report the stabilization of SARS-CoV-2 Wuhan Hu-1 Spike receptor binding domain (S RBD) using a combination of deep mutational scanning and computational design, including the FuncLib algorithm. Our most successful design encodes I358F, Y365W, T430I, and I513L RBD mutations, maintains recognition by the receptor ACE2 and a panel of different anti-RBD monoclonal antibodies, is between 1-2°C more thermally stable than the original RBD using a thermal shift assay, and is less proteolytically sensitive to chymotrypsin and thermolysin than the original RBD. Our approach could be applied to the computational stabilization of a wide range of proteins without requiring detailed knowledge of active sites or binding epitopes, particularly powerful for cases when there are multiple or unknown binding sites.

Identifiers

PMID34845448
PMCPMC8629191
OpenAlexW3217205737

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.